Randomised controlled trialindependent cross-checkabstract only checked★ key study I-BAR-03 in-depth review
Italian 10-year diabetes surgery trial
Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.
Overview
Mingrone G et al.. Lancet 2021 · PMID 33485454 · DOI 10.1016/S0140-6736(20)32649-0
More than half of those in remission at 2 years relapsed, but their sugar control stayed good (HbA1c 6.7%) and complications were fewer than with medicines alone.
Does the study support the specific claim? Partly · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Durability
- How was the study done?
RCT
- How many people, animals or samples were studied?
60
- What was actually found?
Relapse frequent; control better
- How large was the observed effect?
RR complications 0.07
- What do the results mean in everyday life?
Relapse does not mean the benefit is lost
- What are the study's limitations?
Tiny
- What does it say about Elawady's specific claim?
Partly supports
- Do the results apply to Germany and Europe?
European
- What can explicitly not be concluded from this study?
Generalizability
Scientific in-depth review
1. Full reference
- Authors
- Mingrone G et al.
- Journal
- Lancet
- Year
- 2021
- Identifier
- PMID 33485454 DOI 10.1016/S0140-6736(20)32649-0
- Verification
- verified – PubMed efetch 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract
2. Research question
Durability of diabetes remission after RYGB/BPD vs medical therapy
3. Study design and population
- Study design
- Randomised controlled trial – Open-label single-centre RCT, 10-year follow-up
- Population
T2D >5 years, BMI>=35
- Country
Italy
- Period
2009-2021
- Sample size
60
4. Methods and endpoints
- Exposure / intervention
RYGB or BPD
- Comparator
Medical therapy
- Endpoints
Remission; complications
5. Actual results
- Results
10-year remission (ITT): medical 5.5%, BPD 50.0%, RYGB 25.0%. 58.8% of those in remission at 2 years relapsed, but relapsers kept mean HbA1c 6.7%. Diabetes complications RR 0.07 vs medical. Serious adverse events more frequent after BPD (OR 2.7).
- Absolute risks
Remission 25% (RYGB) vs 5.5% (medical) at 10 years
- Authors' conclusion
Metabolic surgery more effective than conventional therapy in long-term control of T2D.
6. Strengths
- Randomized
- 95% follow-up
7. Weaknesses
- Very small
- Single centre
- Open label
8. Risk of bias
- Orienting tool
- RoB 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
9. Assessment of the statistical interpretation
10. Relevance to the specific claim
Documents high relapse rate and persistent glycemic advantage.
11. Independent contrary findings
12. Transferability to Germany and Europe
Directly European.
13. Overall methodological judgement
Supports that relapse is common but control remains better.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | some concerns |
| Precision of results | low |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
15. Linked fact checks
- The diabetes remission achieved by bariatric surgery erodes over time (SOS: 72% at 2 years to 30.4% at 15 years; Adams: 75% to 51%). – Studies with mixed or unclear results
- Gastric bypass is preferable to sleeve gastrectomy (less reflux) and can fully treat type 2 diabetes; for patients who fail dieting, bypass rather than sleeve should be chosen (2021 statement). – Studies contradicting or limiting the claim